{Reference Type}: Journal Article
{Title}: Evaluation and management of residual cardiovascular risk in patients with diabetes.
{Author}: Gimeno Orna JA;Ortez Toro JJ;Peteiro Miranda CM;
{Journal}: Endocrinol Diabetes Nutr (Engl Ed)
{Volume}: 67
{Issue}: 4
{Year}: Apr 2020
{Factor}: 1.833
{DOI}: 10.1016/j.endinu.2019.05.004
{Abstract}: Presence of diabetes (types 1 and 2) increases the risk of atherosclerotic cardiovascular disease. Despite adequate metabolic control and treatment of vascular risk factors until the goals recommended by the clinical practice guidelines are achieved, residual cardiovascular risk may be very high in some patients with diabetes. Stratifying the vascular risk for each patient as precisely as possible is therefore necessary. Consolidated strategies to improve patient prognosis include aggressive reduction of LDL cholesterol, blood pressure control, achievement of the best HbA1c control possible without inducing hypoglycemia, use of hypoglycemic drugs shown to have cardiovascular benefits, and use of platelet aggregation inhibitors in patients with greater initial risk. Emerging strategies for patients with very high or extreme risk would include use of drugs intended to decrease triglyceride-rich lipoproteins and inflammation.